Europe DNA vaccine market was calculated to be at $XX million in the year 2017. The market is projected to expand further at a CAGR of 41.34%, generating around $XX million by the end of the forecast period of 2018-2026. 

EUROPE DNA VACCINE MARKET FORECAST 2018-2026

Europe DNA Vaccine Market by Type (Animal DNA Vaccine, Human DNA Vaccine) by Application (Human Disease, Veterinary Disease) by Technology (Plasmid DNA Vaccines, Plasmid DNA Delivery) by Geography

Request free sample

Europe DNA vaccine market was calculated to be at $XX million in the year 2017. The market is projected to expand further at a CAGR of 41.34%, generating around $XX million by the end of the forecast period of 2018-2026.

Europe DNA vaccine market

To learn more about this report, request a free sample copy

The countries analyzed for this market include the United Kingdom, France, Spain, Germany, along with the rest of Europe. The market is chiefly segmented on the basis of type, application, and technology. The various developments in the field of nanotechnology and biotechnology are significantly responsible for increasing the demand of the market. Also, the fact that these vaccines are comparatively stable than the traditional vaccines makes it easy for their storage and transport. The market finds its application in human as well as veterinary diseases.  Because of the rising global travel of people, animals, and commercial goods, the risk of disease transmission and spread has increased considerably. This, in turn, is largely increasing the demand for the market.

Some of the well-known DNA vaccine market companies include Sanofi, Zoetis Inc, Eurogentec S.A, Astellas Pharma Inc, Eli Lilly And Company, Glaxosmithkline Inc, Merck & Co, Xenetic Biosciences Inc, Inovio Pharmaceuticals Inc, Novartis Ag, Madison Vaccines Incorporated (MVI), and Vical Incorporated.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
    4. MARKET DETERMINANTS
      • DRIVERS
        • DNA VACCINES SHOW GREAT PROMISE IN CHECKING THE RISING PREVALENCE OF DISEASES
        • THIRD GENERATION VACCINATION IS SEEING A SURGE IN INVESTMENT
        • INCREASING ADOPTION OF DNA VACCINES FOR ANIMAL HEALTHCARE
      • RESTRAINTS
        • LENGTHY REGULATORY PROCESS
        • POOR PATENT PROTECTION IN SOME COUNTRIES
      • OPPORTUNITIES
        • TRANSFORMING HEALTHCARE LANDSCAPE
        • NEW DEVELOPMENTS IN BIOTECHNOLOGIES AND NANOTECHNOLOGIES
        • STABLE VACCINES MAKE IT ATTRACTIVE TO STORE AND TRANSPORT
      • CHALLENGES
        • VACCINES FOR HUMAN USAGE STILL UNDER CLINIC TRAIL PHASE
    1. MARKET SEGMENTATION
      • MARKET BY TYPE 2018-2026
        • ANIMAL DNA VACCINE
        • HUMAN DNA VACCINE
      • MARKET BY APPLICATION 2018-2026
        • HUMAN DISEASE
        • VETERINARY DISEASE
      • MARKET BY TECHNOLOGY 2018-2026
        • PLASMID DNA VACCINES
        • PLASMID DNA DELIVERY
    1. KEY ANALYTICS
      • PORTER’S FIVE FORCE MODEL
        • THREAT OF NEW ENTRANTS
        • THREATS OF SUBSTITUTE PRODUCT
        • BARGAINING POWER OF BUYER
        • BARGAINING POWER OF SUPPLIER
        • INTENSITY OF COMPETITIVE RIVALRY
      • KEY BUYING CRITERIA
        • EFFICACY
        • COST-EFFECTIVENESS
        • STABILITY
      • KEY MARKET PLAYERS
        • VICAL INCORPORATED
        • SANOFI
        • MERCK AND CORP
        • GSK
      • OPPORTUNITY MATRIX
      • VALUE CHAIN ANALYSIS
        • R&D
        • MANUFACTURING
        • RAW MATERIALS
        • MARKETING, DISTRIBUTION & END USER
      • LEGAL, POLICY AND REGULATORY FRAMEWORK
    2. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • UNITED KINGDOM
        • FRANCE
        • GERMANY
        • SPAIN
        • REST OF EUROPE
    1. COMPETITIVE LANDSCAPE
      • STRATEGIC INITIATIVES
        • ACQUISITION
        • PARTNERSHIP
        • COLLABORATION
        • INNOVATION
        • DISINVESTMENT
        • EXPANSION
    1. COMPANY PROFILE
      • MARKET SHARE
      • ASTELLAS PHARMA INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • DENDREON CORPORATION (ACQUIRED BY SANPOWER GROUP)
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • ELI LILLY AND COMPANY
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • EUROGENTEC S.A
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • GLAXOSMITHKLINE INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • INOVIO PHARMACEUTICALS, INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • MADISON VACCINES INCORPORATED (MVI)
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
      • MERIAL LIMITED (ACQUIRED BY BOEHRINGER INGELHEIM)
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • MERCK & CO.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • NOVARTIS AG
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • SANOFI
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • VGXI
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • VICAL INCORPORATED
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • XENETIC BIOSCIENCES INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATES
      • ZOETIS INC
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATES

    LIST OF TABLES

    TABLE 1                 EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)

    TABLE 2                 INTERVENTIONS AND PHASE OF CERTAIN DISEASE/CONDITIONS

    TABLE 3                 APPROACHES BEING TESTED TO ENHANCE THE LOW IMMUNOGENICITY

    TABLE 4                 CLINICAL TRIALS OF THE HUMANS INVOLVING DNA VACCINES

    TABLE 5                 TEMPERATURE REQUIREMENTS IN PRESERVATION FOR VARIOUS VACCINES

    TABLE 6                 EUROPE DNA VACCINE MARKET BY TYPE 2018-2026 ($ MILLION)

    TABLE 7                 EUROPE DNA VACCINE MARKET IN ANIMAL DNA VACCINE 2018-2026($MILLION)

    TABLE 8                 EUROPE DNA VACCINE MARKET IN HUMAN DNA VACCINE 2018-2026

    TABLE 9                 EUROPE DNA VACCINE MARKET BY APPLICATION 2018-2026 ($ MILLION)

    TABLE 10     EUROPE DNA VACCINE MARKET IN HUMAN DISEASES APPLICATION 2018-2026 ($MILLION)

    TABLE 11     EUROPE DNA VACCINE MARKET IN VETERINARY APPLICATION 2018-2026

    TABLE 12     EUROPE DNA VACCINE MARKET BY TECHNOLOGY 2018-2026 ($ MILLION)

    TABLE 13     EUROPE DNA VACCINE MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2018-2026

    TABLE 14     EUROPE DNA VACCINE MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2018-2026

    TABLE 15     REGULATONS TO BE FOLLOWED BEFORE COMMERCIALIZATION

    LIST OF FIGURES

    FIGURE 1     EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)

    FIGURE 2     EUROPE DNA VACCINE MARKET IN VETERINARY DISEASES 2018-2026 ($ MILLION)

    FIGURE 3     SHARE OF TRIALS BY VACCINE TARGET IN 2016

    FIGURE 4     SEGMENT OF CLINICAL TRIALS OF DNA VACCINE BY CANCER MARKS IN 2016

    FIGURE 5     CLINICAL TRIALS OF GENE THERAPHY

    FIGURE 6     EUROPE DNA VACCINE MARKET SHARE BY TYPE 2017 & 2026 (%)

    FIGURE 7     EUROPE DNA VACCINES MARKET IN ANIMAL DNA VACCINES 2018-2026 ($ MILLION)

    FIGURE 8     EUROPE DNA VACCINE MARKET IN HUMAN DNA VACCINES 2018-2026($ MILLION)

    FIGURE 9     EUROPE DNA VACCINE MARKET SHARE BY APPLICATION 2017 & 2026 (%)

    FIGURE 10   EUROPE DNA VACCINES MARKET IN HUMAN DISEASES 2018-2026 ($ MILLION)

    FIGURE 11   EUROPE DNA VACCINES MARKET IN VTERINARY APPLICATION 2018-2026 ($ MILLION)

    FIGURE 12   EUROPE DNA VACCINES MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2018-2026 ($ MILLION)

    FIGURE 13   EUROPE DNA VACCINES MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2018-2026 ($ MILLION)

    FIGURE 14   VALUE CHAIN ANALYSES FOR DNA VACCINE INDUSTRY

    FIGURE 15   UNITED KINGDOM DNA VACCINE MARKET 2018-2026 ($ MILLION)

    FIGURE 16   FRANCE DNA VACCINE MARKET 2018-2026 ($ MILLION)

    FIGURE 17   GERMANY DNA VACCINE MARKET 2018-2026 ($ MILLION)

    FIGURE 18   SPAIN DNA VACCINE MARKET 2018-2026 ($ MILLION)

    FIGURE 19   REST OF EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)

    FIGURE 20   MARKET SHARES OF TOP FIVE COMPANIES FOR DNA VACCINES MARKET IN 2017

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • UNITED KINGDOM
        • FRANCE
        • GERMANY
        • SPAIN
        • REST OF EUROPE
    1. MARKET SEGMENTATION
      • MARKET BY TYPE 2018-2026
        • ANIMAL DNA VACCINE
        • HUMAN DNA VACCINE
      • MARKET BY APPLICATION 2018-2026
        • HUMAN DISEASE
        • VETERINARY DISEASE
      • MARKET BY TECHNOLOGY 2018-2026
        • PLASMID DNA VACCINES
        • PLASMID DNA DELIVERY

     

     

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type